SPINRAZA helped maintain motor function in open-label CS2/CS12 studies1

CS2/CS12

Nonambulatory patients (n=11) who were ≤16 years of age with later-onset (Type 2) SMA demonstrated a 10.8-point increase in HFMSE score from baseline of 2.1

Change in HFMSE score in patients with later-onset SMA from baseline after 1150 days1

Chart showing a change in HFMSE score from baseline after 1050 days
Chart showing a change in HFMSE score from baseline after 1050 days

Change in HFMSE score from baseline was strongly correlated with change from baseline in ULM score at every visit day in patients with Type 2 SMA. Progressive improvements in mean ULM score were demonstrated over time (4.0-point increase from baseline).1

HFMSE=Hammersmith Functional Motor Scale—Expanded; SE=standard error; SMA=spinal muscular atrophy; ULM=Upper Limb Module.

In a natural history cohort of later-onset (Types 2 and 3) SMA, mean change was -1.7 points over 36 months (1095 days).1

Emma
age 7

Later-onset (Type 3) SMA
treated with SPINRAZA

Emma
age 7

Later-onset (Type 3) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.